Scadenza: 5 March 2021
Scadenze successive:
Online submission July 1, 2021
Online submission with digital signature of the PI and Legal representative July 15, 2021
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment
Ente finanziatore:
Airc Foundation
Budget complessivo:
The grant is up to € 100.000/year
Duration of the project: 5 years
Who can participate:
Applicants can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career. PIs must be involved in the project for at least 50% of their time. To be eligible, applicants must meet the following eligibility criteria:
be 40 years old or younger by the time of the pre-submission application’s deadline
have at least 3 primary research papers as first/co-first, last/co-last or corresponding/cocorresponding author
have never been awarded an AIRC individual grant before
Status:
Closed
Quota finanziabile:
100%
Topic:
All proposed research plans must have a clear objective that is consistent with the AIRC mission and will likely lead to advances in cancer biology, prevention, monitoring, diagnosis, or treatment of tumors in the near term.
Research plans should fall into one of the following research areas:
• Angiogenesis • Cancer genetics • Cancer stem cells • Cell adhesion, migration, invasion and metastasis • Cell cycle control and cell division • Cell death and apoptosis • Chemotherapy • Computational biology • Control of gene expression and epigenetics • Diagnosis • DNA damage and repair • Epidemiology and prevention • Gene therapy • Hormone therapy • Imaging • Immunotherapy • Infection, inflammation and cancer • Metabolism • Prognosis • Radiobiology and radiotherapy • Resistance to therapy • Signal transduction and intracellular trafficking • Structural biology • Targeted therapy and new therapeutics • Tumor immunology • Tumor microenvironment
Who can participate:
Applicants can be of any nationality and are expected to have operated to the highest standards of integrity during their whole career. PIs must be involved in the project for at least 50% of their time. To be eligible, applicants must meet the following eligibility criteria:
be 40 years old or younger by the time of the pre-submission application’s deadline
have at least 3 primary research papers as first/co-first, last/co-last or corresponding/cocorresponding author
have never been awarded an AIRC individual grant before
Programme:
Consortium:
Status: Open
Total budget:
The grant is up to € 100.000/year
Funding rate:
100%
